Literature DB >> 22941171

Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm.

Jan Franko1, Vladimir Hugec, Tercio L Lopes, Charles D Goldman.   

Abstract

BACKGROUND: Size of primary tumor has implications for staging, imaging, and treatment of pancreatic head carcinomas. Limited data suggest that small tumor size is associated with better survival. The objective of this population study is to analyze characteristics and survival of patients with resected pancreatic head ductal carcinomas sized <1 and 2 cm.
METHODS: Analysis of resected invasive pancreatic head ductal carcinomas captured within SEER Program from 1998 to 2008.
RESULTS: A total of 7,135 cases were analyzed with nodal metastases in 31, 55, and 67 % for subcentimeter, 1.1-2 cm, and >2 cm tumors, respectively. Median survival was longest for node-negative tumors (38, 26, 19 months for tumors measuring ≤ 1, 1.1-2, and >2 cm, respectively; p < 0.001) versus node-positive tumors (18, 19, 14 months, p < 0.001). In multivariate analysis, large tumor size was associated with higher risk of death (hazard ratio (HR) = 1.179 for tumors 1.1-2 cm, p = 0.152; HR = 1.665 for tumors >2 cm, p < 0.001).
CONCLUSIONS: Small pancreatic cancers have a poor prognosis and surprisingly high rate of nodal involvement; therefore, they cannot be considered early cancers. Size-based screening is unlikely to save lives with current treatment options.

Entities:  

Mesh:

Year:  2012        PMID: 22941171     DOI: 10.1245/s10434-012-2621-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer.

Authors:  Birte Kulemann; Jens Hoeppner; Uwe Wittel; Torben Glatz; Tobias Keck; Ulrich F Wellner; Peter Bronsert; Olivia Sick; Ulrich T Hopt; Frank Makowiec; Hartwig Riediger
Journal:  J Gastrointest Surg       Date:  2015-01-08       Impact factor: 3.452

Review 2.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening.

Authors:  Chin Hur; Angela C Tramontano; Emily C Dowling; Gabriel A Brooks; Alvin Jeon; William R Brugge; G Scott Gazelle; Chung Yin Kong; Pari V Pandharipande
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

4.  Poor prognosis of common-type invasive ductal carcinomas that originate in the branching pancreatic duct.

Authors:  Masataka Ando; Yasuhiro Shimizu; Tsuyoshi Sano; Yoshiki Senda; Yuji Nimura; Kenji Yamao; Masato Nagino; Akio Yanagisawa
Journal:  Surg Today       Date:  2014-12-05       Impact factor: 2.549

5.  Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Reclassification of the Tumor Extending Beyond the Pancreas Based on Tumor Size.

Authors:  Masanao Kurata; Goro Honda; Yoshiaki Murakami; Kenichiro Uemura; Sohei Satoi; Fuyuhiko Motoi; Masayuki Sho; Ippei Matsumoto; Manabu Kawai; Hiroaki Yanagimoto; Takumi Fukumoto; Minako Nagai; Masahiko Gosho; Michiaki Unno; Hiroki Yamaue
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

6.  The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.

Authors:  Dietrich A Ruess; Frank Makowiec; Sophia Chikhladze; Olivia Sick; Hartwig Riediger; Ulrich T Hopt; Uwe A Wittel
Journal:  BMC Surg       Date:  2015-11-28       Impact factor: 2.102

7.  Re-defining the role of EUS in pancreatic adenocarcinoma in 2017.

Authors:  Paolo G Arcidiacono
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

8.  The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database.

Authors:  Y Luo
Journal:  Clin Transl Oncol       Date:  2021-07-04       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.